alpelisib alpelisib alpelisib, sold under the brand name piqray among others, is a medication used to treat certain types of breast cancer. it is used together with fulvestrant. it is taken by mouth. it is marketed by novartis. alpelisibclinical datatrade namespiqray, vijoiceother namesbyl719ahfs/drugs.commonographmedlineplusa619036license data eu ema: by inn us dailymed: alpelisib us fda: piqray pregnancycategory au: d routes ofadministrationby mouthatc codel01em03 (who) legal statuslegal status au: s4 (prescription only) ca: ℞-only us: ℞-only eu: rx-only identifiers iupac name (2s)-1-n--1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide cas number1217486-61-7pubchem cid56649450pubchem sid347828332drugbankdb12015chemspider28424123unii08w5n2c97qkeggd11011chebichebi:93752chemblchembl2396661comptox dashboard (epa)dtxsid70153355 echa infocard100.233.704 chemical and physical dataformulac19h22f3n5o2smolar mass441.47 g·mol−13d model (jsmol)interactive image smiles cc1=c(sc(=n1)nc(=o)n2cccc2c(=o)n)c3=cc(=nc=c3)c(c)(c)c(f)(f)f inchi inchi=1s/c19h22f3n5o2s/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12h,4-5,8h2,1-3h3,(h2,23,28)(h,25,26,29)/t12-/m0/s1key:stuwgjzdjhpwgz-lbprgkrzsa-n common side effects include high blood sugar, kidney problems, diarrhea, rash, low blood cells, liver problems, pancreatitis, vomiting, and hair loss. it is an alpha-specific pi3k inhibitor. it was approved for medical use in the united states in may 2019. medical uses alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3ca-mutated, advanced or metastatic breast cancer as detected by an fda-approved test following progression on or after an endocrine-based regimen. in the european union, alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (hr)‑positive, human epidermal growth factor receptor 2 (her2)‑negative, locally advanced or metastatic breast cancer with a pik3ca mutation after disease progression following endocrine therapy as monotherapy. in april 2022, the indication for alpelisib was expanded in the us to include the treatment of severe manifestations of pik3ca-related overgrowth spectrum (pros) in those who require systemic therapy. research dietary supplementation with the pi3ki alpelisib from middle age extends the median (by an average of 10%) and maximal lifespan of mice, an effect that was more pronounced in females. while long-term pi3ki treatment was well tolerated and led to greater strength and balance, negative impacts on common human aging markers, including reductions in bone mass and mild hyperglycemia, were also evident. these results suggest that while pharmacological suppression of insulin receptor (ir)/insulin-like growth factor receptor (igfr) targets could represent a promising approach to delaying some aspects of aging, caution should be taken in translation to humans. history in may 2019, alpelisib was approved in the united states for use in combination with the endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative, pik3ca-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. the u.s. food and drug administration (fda) also approved the companion diagnostic test, therascreen pik3ca rgq pcr kit, to detect the pik3ca mutation in a tissue and/or a liquid biopsy. the efficacy of alpelisib was studied in the solar-1 trial (nct02437318), a randomized trial of 572 postmenopausal women and men with hr-positive, her2-negative, advanced or metastatic breast cancer whose cancer had progressed while on or after receiving an aromatase inhibitor. the fda granted the application for alpelisib priority review designation and granted approval of piqray to novartis. the fda granted approval of the therascreen pik3ca rgq pcr kit to qiagen manchester, ltd. on 28 may 2020, the committee for medicinal products for human use (chmp) of the european medicines agency (ema) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product alpelisib (piqray), intended for the treatment of locally advanced or metastatic breast cancer with a pik3ca mutation. the applicant for this medicinal product is novartis europharm limited. alpelisib was approved for medical use in the european union in july 2020. society and culture legal status alpelisib was approved for medical use in the united states in may 2019, in australia in march 2020, and in the european union in july 2020.